HC Wainwright Has Optimistic View of OPKO Health Q2 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – HC Wainwright raised their Q2 2025 earnings estimates for OPKO Health in a report released on Wednesday, March 12th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s FY2025 earnings at ($0.30) EPS.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million.

A number of other equities analysts also recently issued reports on the stock. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th.

OPKO Health Price Performance

OPK stock opened at $1.81 on Monday. OPKO Health has a 1 year low of $0.86 and a 1 year high of $2.04. The company has a market cap of $1.22 billion, a P/E ratio of -9.53 and a beta of 1.70. The firm has a 50-day moving average of $1.63 and a 200 day moving average of $1.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 47,537 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were acquired at an average price of $1.47 per share, for a total transaction of $69,879.39. Following the completion of the acquisition, the chief executive officer now owns 213,234,014 shares in the company, valued at $313,454,000.58. This trade represents a 0.02 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have acquired 964,971 shares of company stock worth $1,493,692. 47.26% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently made changes to their positions in OPK. FMR LLC grew its holdings in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 12,417 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health during the third quarter valued at approximately $45,000. Cibc World Markets Corp purchased a new stake in OPKO Health in the fourth quarter worth approximately $45,000. Finally, Zacks Investment Management purchased a new stake in OPKO Health in the fourth quarter worth approximately $49,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.